Posted by Michael Wonder on 21 Mar 2023
Prestige Biopharma receives FDA fast track designation for PBP1510 in the treatment of pancreatic cancer
21 March 2023 - Prestige Biopharma has received fast track designation from the US FDA for PBP1510 (ulenistamab), in the treatment of unresectable or metastatic pancreatic adenocarcinoma that has relapsed following and/or is refractory to at least one line of prior therapy.
PBP1510 targets pancreatic adenocarcinoma upregulated factor, a tumour-specific protein, found to be over-expressed in majority of pancreatic cancer cases.
